Drug Search Results
More Filters [+]

Apabetalone

Alternative Names: apabetalone, rvx000222, RVX-208, RVX208
Latest Update: 2024-02-06
Latest Update Note: PubMed Publication

Product Description

Apabetalone has been investigated for the treatment of Diabetes, Atherosclerosis, and Coronary Artery Disease. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Apabetalone)

Mechanisms of Action: BET Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Breakthrough Therapy - Type 2 Diabetes *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Resverlogix Corp
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Apabetalone

Countries in Clinic: Canada

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary|Kidney Failure, Chronic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

RVX222-CS-018

P2

Not yet recruiting

Kidney Failure, Chronic

2026-11-22

24%

APPROACH-2

P2

Not yet recruiting

Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension

2025-03-01

APPRoAcH-p

P1

Completed

Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary

2021-10-15

Recent News Events